Curis | CRIS - Ebitda


Curis reported $-12.3M in EBITDA for its fiscal quarter ending in September of 2023.





Ebitda Change Date
Alaunos Therapeutics USD -21.02M 1.33M Mar/2021
Amgen USD 5.14B 775M Dec/2025
AstraZeneca USD 5.67B 1.29B Mar/2026
Bayer EUR 4.45B 2.49B Mar/2026
Bristol-Myers Squibb USD 2.88B 1.36B Dec/2025
CSL USD 3.13B 1.17B Dec/2025
Curis USD -12.3M 231K Sep/2023
Eli Lilly USD 12.14B 4.26B Dec/2025
Exelixis USD 258.29M 15.43M Mar/2026
Gilead Sciences USD 3.02B 1.01B Dec/2025
GlaxoSmithKline GBP 2.77B 1.65B Mar/2026
Incyte USD 367.97M 46.53M Mar/2026
Merck USD 6.3B 2.09B Dec/2025
Novartis USD 5.3B 530M Mar/2026
Pfizer USD 5.99B 5.23B Mar/2026
Roche Holding CHF 12.68B 2.36B Jun/2024
Sanofi EUR 3.31B 3.65B Mar/2026
Takeda JPY 150.25B 297.88B Mar/2026
TG Therapeutics USD 51.69M 19M Dec/2025
Xoma USD 2.52M 7.98M Jun/2024